West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment [Breast Cancer]
Conclusion
In this prospective trial, patients with enhanced clinical risk and omitted chemotherapy on the basis of RS ≤ 11 had excellent 3-year survival. The substantial discordance observed between traditional prognostic markers and RS emphasizes the need for standardized assessment and supports the potential integration of standardized, well-validated genomic assays such as RS with clinicopathologic prognostic factors for chemotherapy indication in early hormone receptor–positive BC.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Gluz, Nitz, Christgen, Kates, Shak, Clemens, Kraemer, Aktas, Kuemmel, Reimer, Kusche, Heyl, Lorenz-Salehi, Just, Hofmann, Degenhardt, Liedtke, Svedman, Wuerstlein, Kreipe, Harbeck Tags: Chemotherapy, Hormonal Therapy, Clinical Trials, Prognostic Studies Breast Cancer Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Endocrine Therapy | Genetics | Hormonal Therapy | Hormones | Pathology | Study